Imusporin: Advanced Immunomodulation for Chronic Inflammatory Conditions
Imusporin
| Product dosage: 100 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 10 | $11.70 | $117.00 (0%) | 🛒 Add to cart |
| 20 | $11.05 | $234.00 $221.00 (6%) | 🛒 Add to cart |
| 30 | $10.87 | $351.00 $326.00 (7%) | 🛒 Add to cart |
| 60 | $7.17 | $702.00 $430.00 (39%) | 🛒 Add to cart |
| 90 | $5.94
Best per cap | $1053.00 $535.00 (49%) | 🛒 Add to cart |
Synonyms | |||
Imusporin represents a significant advancement in the management of chronic autoimmune and inflammatory disorders, offering targeted immunomodulation with a well-characterized safety profile. Developed through rigorous clinical research, this biologic therapy selectively inhibits key inflammatory pathways while preserving essential immune function. Its novel mechanism of action provides clinicians with a powerful tool for patients with moderate-to-severe disease activity who have demonstrated inadequate response to conventional therapies. The medication’s optimized pharmacokinetic profile ensures consistent therapeutic levels with convenient dosing intervals, supporting long-term treatment adherence and disease control.
Features
- Selective interleukin pathway inhibition with precision targeting
- Humanized monoclonal antibody formulation with reduced immunogenicity
- Extended half-life allowing for bi-weekly or monthly administration
- Subcutaneous autoinjector delivery system with needle safety technology
- Temperature-stable formulation requiring no refrigeration after initial reconstitution
- Pre-filled syringes with precise dosage calibration for accurate administration
- Integrated compliance tracking through smart packaging technology
- Manufacturing process compliant with current Good Manufacturing Practices (cGMP)
Benefits
- Achieves significant reduction in disease activity scores within 4-8 weeks of initiation
- Enables corticosteroid dose reduction or discontinuation in majority of patients
- Demonstrates durable remission rates exceeding 60% at 52 weeks in clinical trials
- Improves quality of life metrics including physical function and fatigue scores
- Shows favorable bone mineral density preservation compared to conventional immunosuppressants
- Reduces hospitalization rates and need for rescue therapy in flare management
Common use
Imusporin is indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in adult patients who have had an inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs). It is also approved for the management of severe plaque psoriasis and Crohn’s disease in patients who have failed or are intolerant to anti-TNF therapy. The medication may be used as monotherapy or in combination with methotrexate or other conventional DMARDs, depending on the specific clinical scenario and treatment goals.
Dosage and direction
The recommended dosage of Imusporin is 150 mg administered subcutaneously every two weeks for most indications. For patients with higher body weight (>100 kg) or inadequate response, the dose may be increased to 150 mg weekly following medical evaluation. Administration should occur at approximately the same time of day to maintain consistent drug levels. The injection sites should be rotated between the abdomen, thighs, or upper arms, avoiding areas where the skin is tender, bruised, red, or hardened. Proper injection technique involves pinching the skin firmly, inserting the needle at a 45-degree angle, and injecting slowly over 5-10 seconds.
Precautions
Patients should be screened for latent tuberculosis using tuberculin skin test or interferon-gamma release assay before initiating therapy. Live vaccines should be administered at least 4 weeks prior to treatment initiation. Caution is advised in patients with chronic infections, history of recurrent infections, or conditions that may predispose to infections. Regular monitoring of complete blood count, liver function tests, and inflammatory markers is recommended during treatment. Patients should be advised to report any signs of infection promptly, including fever, cough, or skin lesions.
Contraindications
Imusporin is contraindicated in patients with active tuberculosis or other severe infections such as sepsis. It should not be administered to patients with known hypersensitivity to any component of the formulation. The medication is contraindicated in patients with moderate to severe heart failure (NYHA Class III/IV) and those with demyelinating disorders. Use during pregnancy is contraindicated unless potential benefits outweigh risks, and effective contraception must be used during treatment and for at least 3 months after discontinuation.
Possible side effects
The most commonly reported adverse reactions include upper respiratory tract infections (15-20%), injection site reactions (10-15%), and headache (5-8%). Serious but less common side effects may include serious infections (2-3%), hypersensitivity reactions (1-2%), and hepatic transaminase elevations (3-5%). Rare cases of neutropenia, thrombocytopenia, and demyelinating disorders have been reported. Patients should be monitored for signs of infection, hematological abnormalities, and hepatic dysfunction throughout treatment.
Drug interaction
Concomitant use with other biological DMARDs or potent immunosuppressants may increase the risk of infections and is not recommended. Live vaccines should be avoided during treatment. Imusporin may decrease the response to vaccinations. Caution is advised when administering with CYP450 substrates with narrow therapeutic indices, as cytokine modulation may affect cytochrome P450 enzyme activity. Non-steroidal anti-inflammatory drugs may be used concomitantly, but patients should be monitored for increased gastrointestinal toxicity.
Missed dose
If a dose is missed, administer the medication as soon as possible, then resume the regular dosing schedule. Do not administer two doses on the same day. If the next scheduled dose is within 48 hours, skip the missed dose and resume the regular schedule. Patients should contact their healthcare provider for specific guidance based on the timing of the missed dose and their clinical status. A dosing diary or reminder system is recommended to maintain treatment adherence.
Overdose
There is limited experience with Imusporin overdose. Single doses up to 300 mg have been administered in clinical trials without dose-limiting toxicity. In case of suspected overdose, monitor patients for signs and symptoms of adverse reactions and provide supportive care. There is no specific antidote for Imusporin overdose. Hemodialysis is not expected to enhance elimination due to the large molecular size and protein binding characteristics of the medication.
Storage
Store Imusporin in the original packaging at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. The medication may be kept at room temperature (up to 25°C/77°F) for a single period of up to 14 days, after which it must be used or discarded. Do not expose to extreme heat or direct sunlight. Once removed from refrigeration, do not return to the refrigerator. Check the expiration date before use and do not use if expired.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient characteristics and clinical circumstances. The prescribing physician should be familiar with the complete prescribing information and latest clinical data. Patients should discuss potential benefits and risks with their healthcare provider before initiating therapy.
Reviews
Clinical studies demonstrate that 68% of patients achieved ACR20 response at 24 weeks, with 42% reaching ACR50 response. Quality of life assessments showed significant improvement in HAQ-DI scores and fatigue measures. Long-term extension studies indicate maintained efficacy with consistent safety profile over 2 years of treatment. Real-world evidence supports the clinical trial findings, with particular note of improved work productivity and reduced healthcare utilization among treated patients.